Evolent Health (FRA:9EH) Beneish M-Score: -3.37 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9EH Evolent Health Inc FRA:9EH
63 GF Score
Price €5.05
GF Value €9.69
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Evolent Health Beneish M-Score?

Evolent Health FRA:9EH +3.06% 63 Beneish M-Score is -3.37 as of Jul. 21, 2026. GuruFocus rates FRA:9EH with a GF Score™ of 63/100 and a GF Value™ of €9.69 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 628 Healthcare Providers & Services companies, Evolent Health ranks better than 87.74% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.37 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Evolent Health's Beneish M-Score or its related term are showing as below:

FRA:9EH' s Beneish M-Score Range Over the Past 10 Years
Min: -3.42   Med: -2.28   Max: 12.26
Current: -3.37

During the past 13 years, the highest Beneish M-Score of Evolent Health was 12.26. The lowest was -3.42. And the median was -2.28.


Evolent Health Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Evolent Health's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolent Health Beneish M-Score Chart

Evolent Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.78 -1.49 -2.10 -2.15 -3.42

Evolent Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.36 -2.48 -2.71 -3.42 -3.37

FRA:9EH vs PHR, CTEV, MDRX: Beneish M-Score Comparison

For the Health Information Services subindustry, Evolent Health's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolent Health Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Evolent Health's Beneish M-Score falls into.


FRA:9EH
63GF Score
Evolent Health Inc FRA:9EH
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolent Health Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Evolent Health for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9357+0.528 * 0.7549+0.404 * 0.9886+0.892 * 0.7293+0.115 * 1.0282
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.4479+4.679 * -0.064625-0.327 * 1.3676
=-3.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €272 Mil.
Revenue was 429.253 + 400.286 + 408.562 + 385.232 = €1,623 Mil.
Gross Profit was 72.465 + 83.054 + 85.007 + 87.034 = €328 Mil.
Total Current Assets was €434 Mil.
Total Assets was €1,625 Mil.
Property, Plant and Equipment(Net PPE) was €74 Mil.
Depreciation, Depletion and Amortization(DDA) was €97 Mil.
Selling, General, & Admin. Expense(SGA) was €256 Mil.
Total Current Liabilities was €330 Mil.
Long-Term Debt & Capital Lease Obligation was €845 Mil.
Net Income was -23.037 + -366.478 + -17.776 + -17.251 = €-425 Mil.
Non Operating Income was 0.632 + -334.961 + -2.568 + -10.612 = €-348 Mil.
Cash Flow from Operations was -0.851 + 41.675 + 13.472 + -26.3 = €28 Mil.
Total Receivables was €398 Mil.
Revenue was 447.375 + 617.448 + 559.882 + 601.198 = €2,226 Mil.
Gross Profit was 94.786 + 72.304 + 72.704 + 99.257 = €339 Mil.
Total Current Assets was €673 Mil.
Total Assets was €2,454 Mil.
Property, Plant and Equipment(Net PPE) was €74 Mil.
Depreciation, Depletion and Amortization(DDA) was €105 Mil.
Selling, General, & Admin. Expense(SGA) was €243 Mil.
Total Current Liabilities was €684 Mil.
Long-Term Debt & Capital Lease Obligation was €613 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(271.747 / 1623.333) / (398.209 / 2225.903)
=0.167401 / 0.178898
=0.9357

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(339.051 / 2225.903) / (327.56 / 1623.333)
=0.152321 / 0.201782
=0.7549

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (434.239 + 73.566) / 1625.203) / (1 - (673.339 + 74.154) / 2454.442)
=0.687544 / 0.695453
=0.9886

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1623.333 / 2225.903
=0.7293

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(104.742 / (104.742 + 74.154)) / (97.29 / (97.29 + 73.566))
=0.585491 / 0.569427
=1.0282

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(256.35 / 1623.333) / (242.776 / 2225.903)
=0.157916 / 0.109069
=1.4479

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((844.799 + 329.768) / 1625.203) / ((613.383 + 683.665) / 2454.442)
=0.72272 / 0.528449
=1.3676

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-424.542 - -347.509 - 27.996) / 1625.203
=-0.064625

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Evolent Health has a M-score of -3.41 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.37 mean?
Evolent Health (FRA:9EH) has a Beneish M-Score of -3.37 as of Jul. 21, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Evolent Health and its competitors. According to the industry distribution chart, Evolent Health ranks #77 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 12.3%.
Is Evolent Health's Beneish M-Score too high?
Evolent Health's current Beneish M-Score is -3.37. Based on the distribution chart, Evolent Health ranks #77 out of 628 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Evolent Health has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolent Health's Beneish M-Score compare to PHR and CTEV?
According to the Healthcare Providers & Services industry distribution chart, Evolent Health ranks #77 out of 628 companies for Beneish M-Score. This places Evolent Health in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Evolent Health and its competitors. Evolent Health's current Beneish M-Score is -3.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolent Health stock overvalued right now?
Based on GuruFocus' analysis, Evolent Health (FRA:9EH) is currently considered Possible Value Trap. The stock's GF Value™ is €9.69, compared to a current price of €5.05 — trading 47.9% below its estimated fair value. The current Beneish M-Score is -3.37. Evolent Health's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Evolent Health (FRA:9EH), the current Beneish M-Score is -3.37 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolent Health (FRA:9EH) Overvalued in 2026?

Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued. The current stock price of €5.05 is trading 47.9% below its estimated GF Value™ of €9.69. GuruFocus considers Evolent Health to be Possible Value Trap.

Key valuation signals for FRA:9EH:

  • Beneish M-Score: -3.37
  • GF Value™: €9.69 vs. price of €5.05 (47.9% below fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the FRA:9EH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evolent Health Business Description

Other Exchanges EVH:USA9EH:Germany
Address 1812 North Moore Street, Suite 1705, Arlington, VA, USA, 22209
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
63GF Score

Get the complete analysis for FRA:9EH

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.05
Price
€9.69
GF Value